Progyny, Inc. (PGNY) Stock Analysis

Q: What is the PGNY stock price target?

Take-profit $23.89 (+31.8% upside). Prior stop was $16.92.

Q: Is PGNY overvalued or undervalued?

Progyny, Inc. trades at a P/E of 28.3 (forward 8.8). TrendMatrix value score: 8.2/10. Overall verdict: Sell.

Q: What do analysts say about PGNY?

17 analysts cover PGNY with a consensus score of 4.2/5. Average price target: $27.

Recovery setup

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Healthcare Plans

Earnings in 7 days (2026-05-07). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Multiple concerning factors at $18.17: Leverage penalty (D/E 5.4): -1.5; Earnings in 7 days (event risk).

$18.17+31.8% A.UpsideScore 5.6/10#1 of 11 Healthcare Plans

Stop $16.92Target $23.89(analyst − 13%)A.R:R 2.9:1

Analyst target$27.45+51.1%11 analysts

$23.89our TP

$18.17price

$27.45mean

$31

Sell if holding. Multiple concerning factors at $18.17: Leverage penalty (D/E 5.4): -1.5; Earnings in 7 days (event risk). Chart setup: Death cross but MACD improving, RSI 71. Score 5.6/10, moderate confidence.

Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: aggressive.

Thesis

Rewards

Strong earnings beat streak (4/4)

Attractive valuation

Analyst upside: 32%

Risks

Leverage penalty (D/E 5.4): -1.5

Earnings in 7 days (event risk)

Elevated risk factors

Key Metrics

P/E (TTM)28.3

P/E (Fwd)8.8

Mkt Cap$1.5B

EV/EBITDA12.5

Profit Mgn4.5%

ROE12.5%

Rev Growth6.7%

Beta0.99

DividendNone

Rating analysts17

Quality Signals

Piotroski F7/9

Options Flow

P/C3.00bearish

IV90%elevated

Max Pain$35+92.6% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value8.215%1.23

Quality5.315%0.79

Growth5.215%0.78

Momentum5.710%0.57

Sentiment7.310%0.73

Insider Activity5.010%0.50

Peer Rank3.410%0.34

Technical Setup2.95%0.14

Risk Profile3.75%0.19

Catalyst7.55%0.38

Overall (Σ contributions)5.65

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position

2.6

Support Resistance

3.0

Bollinger

3.2

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank

1.4

Growth Rank

3.6

Quality Rank

8.6

Superior ROE vs peersBest-in-class margins

GatesEARNINGS PROXIMITY 7d<=7dDeath cross (50MA < 200MA)Momentum 5.7>=5.5A.R:R 2.9 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive

RSI

71 · Overbought

↑ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $16.10Resistance $18.98

Price Targets

$17

$24

A.Upside+31.5%

A.R:R2.9:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeCautious

Risk Alerts

! EARNINGS_PROXIMITY:7d<=7d

Earnings

4/4 beats

Next Earnings2026-05-07 (7d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is PGNY stock a buy right now?

Sell if holding. Multiple concerning factors at $18.17: Leverage penalty (D/E 5.4): -1.5; Earnings in 7 days (event risk). Chart setup: Death cross but MACD improving, RSI 71. Prior stop was $16.92. Score 5.6/10, moderate confidence.

What is the PGNY stock price target?

Take-profit target: $23.89 (+31.8% upside). Prior stop was $16.92. Stop-loss: $16.92.

What are the risks of investing in PGNY?

Leverage penalty (D/E 5.4): -1.5; Earnings in 7 days (event risk); Elevated risk factors.

Is PGNY overvalued or undervalued?

Progyny, Inc. trades at a P/E of 28.3 (forward 8.8). TrendMatrix value score: 8.2/10. Verdict: Sell.

What do analysts say about PGNY?

17 analysts cover PGNY with a consensus score of 4.2/5. Average price target: $27.

What does Progyny, Inc. do?Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits...

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.